



Universiteit
Leiden

The Netherlands

Refinement of antisense oligonucleotide mediated exon skipping as therapy for Duchenne muscular dystrophy

Heemskerk, J.A.

Citation

Heemskerk, J. A. (2011, October 26). *Refinement of antisense oligonucleotide mediated exon skipping as therapy for Duchenne muscular dystrophy*. Retrieved from <https://hdl.handle.net/1887/17986>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17986>

Note: To cite this publication please use the final published version (if applicable).

Refinement of antisense oligonucleotide
mediated exon skipping as therapy for
Duchenne muscular dystrophy

Hans Heemskerk

Cover: drawings by Satriyo Kurnia

Printed by: Off Page

ISBN: 978-94-6182-030-3

© 2011 Hans Heemskerk. All rights reserved. Copyright of the individual chapters rests with the authors, except (parts of):

Chapter 2 and 3: John Wiley and sons

Chapter 4 and 5: Nature Publishing Group

Chapter 6: Humana Press

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.

Refinement of antisense oligonucleotide mediated exon skipping as therapy for Duchenne muscular dystrophy

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 26 oktober 2011
klokke 11.15 uur

door

Johannes Antonius Heemskerk

geboren te Haarlem in 1979

Promotiecommissie

Promotor: Prof. Dr. Gert-Jan B. van Ommen

Co-promotor: Dr. Annemieke Aartsma-Rus

Overige leden: Prof. Dr. Johan T den Dunnen
Prof. Dr. Jan Verschuuren
Dr. Jennifer E Morgan
(UCL Institute of Child Health, Londen, GB)

The studies described in this thesis have been performed at the Leiden University Medical Center, department of human genetics. This work was financially supported by the Dutch Duchenne Parent Project, the Center for Biomedical Genetics, ZonMw, Senternovem, the TREAT-NMD network of excellence and Telethon Italy.

Table of contents

| | |
|---|------------|
| Chapter 1 | 7 |
| General introduction | |
| 1.1 Duchenne muscular dystrophy | 9 |
| 1.2 Treatment of DMD | 19 |
| 1.2.1 Current treatment | 19 |
| 1.2.2 Potential therapies | 21 |
| 1.3 Antisense oligonucleotide mediated exon skipping | 29 |
| 1.3.1 Refinement of antisense oligonucleotide mediated exon skipping | 32 |
| 1.4 Concluding remarks | 42 |
| 1.5 References | 44 |
| Chapter 2 | 65 |
| <i>In vivo</i> comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping | |
| Chapter 3 | 77 |
| Development of antisense-mediated exon skipping as a treatment for Duchenne muscular dystrophy | |
| Chapter 4 | 89 |
| Pre-clinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the <i>mdx</i> mouse model | |
| Chapter 5 | 99 |
| Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne muscular dystrophy | |
| Chapter 6 | 109 |
| Identification of peptides for tissue specific delivery | |
| Summary | 133 |
| Nederlandse samenvatting | 136 |
| Abbreviations | 139 |
| Curriculum vitae | 140 |
| Publication list | 141 |
| Dankwoord | 142 |

